As increased RANKL activity is observed in patients with bone destructive diseases such as osteoporosis, rheumatoid arthritis, and bone metastases, the RANKL-RANK-OPG axis is considered to be the most relevant therapeutic target for bone destructive diseases [11]. Here, TNFSF11 is linked to osteoporosis.